Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Agnieszka Wozniak"'
Autor:
Arthur O. Frankel, Melvin Lathara, Celine Y. Shaw, Owen Wogmon, Jacob M. Jackson, Mattie M. Clark, Navah Eshraghi, Stephanie E. Keenen, Andrew D. Woods, Reshma Purohit, Yukitomo Ishi, Nirupama Moran, Mariko Eguchi, Farhat Ul Ain Ahmed, Sara Khan, Maria Ioannou, Konstantinos Perivoliotis, Pin Li, Huixia Zhou, Ahmad Alkhaledi, Elizabeth J. Davis, Danielle Galipeau, R.L. Randall, Agnieszka Wozniak, Patrick Schoffski, Che-Jui Lee, Paul H. Huang, Robin L. Jones, Brian P. Rubin, Morgan Darrow, Ganapati Srinivasa, Erin R. Rudzinski, Sonja Chen, Noah E. Berlow, Charles Keller
Publikováno v:
Modern Pathology. 35:1193-1203
Correctly diagnosing a rare childhood cancer such as sarcoma can be critical to assigning the correct treatment regimen. With a finite number of pathologists worldwide specializing in pediatric/young adult sarcoma histopathology, access to expert dif
Autor:
Britt Van Renterghem, Agnieszka Wozniak, Patricia Garrido Castro, Patrick Franken, Nora Pencheva, Raf Sciot, Patrick Schöffski
Publikováno v:
International Journal of Molecular Sciences; Volume 23; Issue 14; Pages: 7493
Doxorubicin (doxo) remains the standard of care for patients with advanced soft tissue sarcoma (STS), even though response rates to doxo are only around 14% to 18%. We evaluated enapotamab vedotin (EnaV), an AXL-specific antibody-drug conjugate (ADC)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37aa190b00b8fd0cefc8d9707b5c5d5e
https://lirias.kuleuven.be/handle/20.500.12942/700064
https://lirias.kuleuven.be/handle/20.500.12942/700064
Autor:
Jasmien Wellens, Keith R. Mehalek, Harbir S. Dhillon, Agnieszka Wozniak, Sneha S. Patil, Aya Agha, Kathleen R. Makielski, Yemarshet K. Gebreyohannes, Areej A. Ali, Anette Duensing, Jessica L. Rausch, Maria Debiec-Rychter, Yanis Tolstov, Patrick Schöffski, Donna M. Lee
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-14 (2020)
Scientific Reports
Scientific Reports
The majority of gastrointestinal stromal tumors (GISTs) are driven by oncogenic KIT signaling and can therefore be effectively treated with the tyrosine kinase inhibitor (TKI) imatinib mesylate. However, most GISTs develop imatinib resistance through
Autor:
Andrea Casazza, Lawrence Van Helleputte, Britt Van Renterghem, Peter Pokreisz, Natalie De Geest, Marzia De Petrini, Tom Janssens, Marijke Pellens, Marjan Diricx, Carla Riera-Domingo, Agnieszka Wozniak, Massimiliano Mazzone, Patrick Schöffski, Olivier Defert, Geert Reyns, Nele Kindt
Publikováno v:
Molecular cancer therapeutics. 21(4)
Clinical use of doxorubicin (Dox) is limited by cumulative myelo- and cardiotoxicity. This research focuses on the detailed characterization of PhAc-ALGP-Dox, a targeted tetrapeptide prodrug with a unique dual-step activation mechanism, designed to c
Autor:
Yannick Wang, Agnieszka Wozniak, Jasmien Cornillie, Pablo Avilés, Maria Debiec-Rychter, Raf Sciot, Patrick Schöffski
Publikováno v:
International Journal of Molecular Sciences; Volume 23; Issue 13; Pages: 7454
A clinically relevant subset of patients with soft tissue sarcoma presents with either locally advanced or upfront metastatic disease, or will develop distant metastases over time, despite successful treatment of their primary tumour. The currently a
Autor:
Patrick Schöffski, Thomas Simmet, Eva Eßeling, Magdalene Cyra, Susanne Hafner, Sandra Elges, Olle Larsson, Jan-Henrik Mikesch, Sareetha Kailayangiri, Inga Grünewald, Bianca Altvater, Agnieszka Wozniak, Sebastian Huss, Claudia Rossig, Wolfgang Hartmann, Eva Wardelmann, Marcel Trautmann, Ilka Isfort, Konrad Steinestel
Publikováno v:
Clinical Cancer Research. 25:3718-3731
Purpose: Synovial sarcoma is a soft tissue malignancy characterized by a reciprocal t(X;18) translocation. The chimeric SS18-SSX fusion protein acts as a transcriptional dysregulator representing the major driver of the disease; however, the signalin
Autor:
Hazem Wafa, Jasmien Cornillie, Patrick Schöffski, Agnieszka Wozniak, Haifu Li, Ulla Vanleeuw, Jasmien Wellens, Diether Lambrechts, Friedl Sinnaeve, Maria Debiec-Rychter, Raf Sciot, Yannick Wang, Daphne Hompes, Bram Boeckx, Yemarshet K. Gebreyohannes, Marguerite Stas
Publikováno v:
Molecular Cancer Therapeutics. 18:1168-1178
Soft-tissue sarcomas (STS) represent a heterogeneous group of rare, malignant tumors of mesenchymal origin. Reliable in vivo sarcoma research models are scarce. We aimed to establish and characterize histologically and molecularly stable patient-deri
Autor:
Olli Kallioniemi, Markku Varjosalo, Katherine Icay, John Patrick Mpindi, Olli Tynninen, Sampsa Hautaniemi, Agnieszka Wozniak, Astrid Murumägi, Evgeny Kulesskiy, Pirjo Laakkonen, Yemarshet K. Gebreyohannes, Maria Laaksonen, Rainer Lehtonen, Heikki Joensuu, Olli-Pekka Pulkka, Krister Wennerberg, Harri Sihto, Salla Keskitalo, Patrick Schöffski, Alejandra Cervera
Publikováno v:
Clinical Cancer Research. 25:1676-1687
Purpose: Gastrointestinal stromal tumor (GIST) is a common type of soft-tissue sarcoma. Imatinib, an inhibitor of KIT, platelet-derived growth factor receptor alpha (PDGFRA), and a few other tyrosine kinases, is highly effective for GIST, but advance
Autor:
Jasmien Cornillie, Madalina-Elena Zhai, Christoph Lengauer, Raf Sciot, Jasmien Wellens, Agnieszka Wozniak, Yemarshet K. Gebreyohannes, Ulla Vanleeuw, Maria Debiec-Rychter, Alexandra K. Gardino, Erica Evans, Patrick Schöffski
Publikováno v:
Clinical Cancer Research. 25:609-618
Purpose: Gastrointestinal stromal tumors (GIST) are commonly treated with tyrosine kinase inhibitors (TKI). The majority of patients with advanced GIST ultimately become resistant to TKI due to acquisition of secondary KIT mutations, whereas primary
Autor:
Yemarshet K. Gebreyohannes, Jasmien Wellens, Daphne Hompes, Patrick Schöffski, Agnieszka Wozniak, Britt Van Renterghem, Maria Debiec-Rychter, Jasmien Cornillie, Raf Sciot, Nathalie Van Winkel
Publikováno v:
BMC Cancer
BMC Cancer, Vol 19, Iss 1, Pp 1-12 (2019)
BMC Cancer, Vol 19, Iss 1, Pp 1-12 (2019)
Background Soft tissue sarcoma (STS) comprises a family of rare, heterogeneous tumors of mesenchymal origin. Single-agent doxorubicin remains the first-line standard-of-care treatment for advanced and inoperable STS, but response rates are only aroun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::255416e11d56f739ae90012cfcceaaca
https://lirias.kuleuven.be/handle/123456789/639986
https://lirias.kuleuven.be/handle/123456789/639986